Deciphera Pharmaceuticals Inc DCPH
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 86.48M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.62
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 355
- Website
- https://www.deciphera.com
Valuation
Metric | DCPH |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 6.65 |
Price/Sales | 12.62 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | DCPH |
|---|---|
Quick Ratio | 3.68 |
Current Ratio | 4.19 |
Interest Coverage | — |
Quick Ratio
DCPH
Profitability
Metric | DCPH |
|---|---|
Return on Assets (Normalized) | −29.00% |
Return on Equity (Normalized) | −37.54% |
Return on Invested Capital (Normalized) | −39.16% |
Return on Assets
DCPH
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|fsF<jmp | LOCK|Qg^? | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|@TGY$ZV | LOCK|dKG< | $48B | |||
| Haleon PLC ADR HLN | LOCK|pLvrGXh | LOCK|nC# | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|cTJwvyT | LOCK|>zN | $32B | |||
| Viatris Inc VTRS | LOCK|$p$lFXP | LOCK|bb | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|Mn | LOCK|^b | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|WCJVC? | LOCK|!#Y | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|@<d@@y | LOCK|>< | $6B | |||
| Perrigo Co PLC PRGO | LOCK|k%!>?X | LOCK|<%% | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|>jH!C%m | LOCK|@H>X | $2B |
United States